Jasper Therapeutics

Yahoo Finance • 4 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR).   Such investors are advised to contact Danielle Peyton at... Full story

Yahoo Finance • 26 days ago

Jasper Therapeutics' SWOT analysis: briquilimab stock faces pivotal moment

Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biopharmaceutical company focused on developing treatments for chronic urticaria, stands at a critical juncture as it navigates recent setbacks and prepares for crucial data readouts. With a marke... Full story

Yahoo Finance • last month

Jasper Therapeutics cuts workforce by 50% to focus on urticaria programs

REDWOOD CITY, Calif. - Jasper Therapeutics, Inc. (NASDAQ:JSPR) announced Wednesday a corporate reorganization that includes cutting approximately 50% of its workforce as the clinical-stage biotechnology company narrows its focus to briquil... Full story

Yahoo Finance • last month

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif.,... Full story

Yahoo Finance • last month

Jasper Therapeutics stock downgraded by BMO Capital on CSU trial concerns

Investing.com - BMO Capital downgraded Jasper Therapeutics (NASDAQ:JSPR) from Outperform to Market Perform on Monday, while maintaining a price target of $4.00. The stock, currently trading at $3.04, has experienced significant volatility,... Full story

Yahoo Finance • last month

Jasper Therapeutics stock price target lowered to $20 by Evercore ISI

Investing.com - Evercore ISI reduced its price target on Jasper Therapeutics (NASDAQ:JSPR) to $20.00 from $50.00 on Monday, while maintaining an Outperform rating on the stock. The company’s shares, currently trading at $3.04, have shown s... Full story

Yahoo Finance • last month

Jasper Therapeutics stock rating reiterated at Buy by TD Cowen despite trial delay

Investing.com - TD Cowen has reiterated its Buy rating on Jasper Therapeutics (NASDAQ:JSPR), currently trading at $3.27, despite the company announcing delays in its clinical trial timeline due to issues with a drug product lot. According... Full story

Yahoo Finance • last month

Jasper Therapeutics stock downgraded by William Blair on drug trial setbacks

Investing.com - William Blair downgraded Jasper Therapeutics (NASDAQ:JSPR) from Outperform to Market Perform on Monday following complications in the company’s clinical trials for briquilimab. The stock, which has seen a -68% year-to-date... Full story

Yahoo Finance • last month

H.C. Wainwright lowers Jasper Therapeutics stock price target on program delays

Investing.com - H.C. Wainwright reduced its price target on Jasper Therapeutics (NASDAQ:JSPR) to $20.00 from $40.00 on Monday, while maintaining a Buy rating on the stock. The company, currently trading at $3.09, appears undervalued accord... Full story

Yahoo Finance • last month

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks Results fr... Full story

Yahoo Finance • 2 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of... Full story

Yahoo Finance • 2 months ago

Jasper Therapeutics' SWOT analysis: briquilimab's potential in CSU stock scrutinized

Jasper Therapeutics (NASDAQ:JSPR), a biopharmaceutical company focused on developing treatments for chronic spontaneous urticaria (CSU) and other mast-cell mediated diseases, has been garnering attention from investors and analysts alike.... Full story

Yahoo Finance • 2 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to... Full story

Yahoo Finance • 3 months ago

Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Jasper Therapeutics, Inc. (JSPR) was one of the stocks that was covered in that article. Wall Street analysts believe JSPR has a 914% upside potential ove... Full story

Yahoo Finance • 5 months ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address... Full story

Yahoo Finance • 5 months ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address... Full story

Yahoo Finance • 6 months ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to... Full story

Yahoo Finance • 6 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to... Full story

Yahoo Finance • 6 months ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to... Full story

Yahoo Finance • 2 years ago

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

REDWOOD CITY, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-drive... Full story